AMP Europe 2018: Immunotherapies

Please note that this content was created in 2018. In the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.

AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.

This is a recording of a session from AMP Europe 2018 meeting in Rotterdam. Purchase the entire AMP Europe 2018 Recordings for a significant discount!

This session will provide an update on immunotherapies as well as insights into tumor mutational burden (TMB) and microsatellite instability (MSI) as predictors of response to treatment with checkpoint blockers.

Objectives:

• Understand the underlying concept and biology of immunooncology (IO) and checkpoint blockade in particular.
• Understand and describe the emerging role of genomic biomarkers predicting IO response.
• Describe and interpret the design and characteristics of assays measuring TMB and MSI.

Duration: 1.25 hr
Recording Date: May 2, 2018

Last day to purchase: December 31, 2021

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.